PORCINE NOROVIRUS
LEVELS: Highly unlikely: No controls necessary; Highly unlikely: No evidence of non-foodborne zoonotic transmission; Moderately effective: Requires high level of compliance with extraordinary on-farm biosecurity measures to prevent farm-to-farm transmission; Difficult: Clinical signs not unique and test(s) not available at local/regional laboratory; Minor: Low prevalence, typically non-lethal infection with recovery very likely; Negligible: Little or no market disruption when disease occurs on one or more farms; Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments; Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy; No availability: Effective treatments not currently available in the US (or have not been developed); No availability: Effective vaccines not currently available in the US (or have not been developed); Difficult and uncertain: Extremely difficult and with uncertain success rate, few global examples of success even at farm level
OVERVIEW
Porcine noroviruses are genetically diverse caliciviruses that are widely distributed in swine populations worldwide. In contrast to human noroviruses, porcine noroviruses are typically subclinical in pigs and have an unclear role in naturally occurring disease. Their primary significance lies in theoretical public-health interest rather than production impact.
FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Highly unlikely: No controls necessary
There is no evidence that porcine noroviruses are transmitted to humans through pork or pork products.
NON-FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Highly unlikely: No evidence of non-foodborne zoonotic transmission
Although genetic and antigenic similarities to human noroviruses raise theoretical concerns, there is no evidence of routine or efficient transmission from pigs to humans.
EFFECTIVENESS OF ON-FARM BIOSECURITY IN PREVENTING FARM-TO-FARM TRANSMISSION
Level: Moderately effective: Requires high level of compliance with extraordinary on-farm biosecurity measures to prevent farm-to-farm transmission
Transmission is presumed fecal–oral with environmental persistence. Wildlife reservoirs exist, but pig-to-pig transmission remains dominant.
DIFFICULTY OF DETECTING AND CONFIRMING INFECTION
Level: Difficult: Clinical signs not unique and test(s) not available at local/regional laboratory
No validated diagnostic tests are available outside research laboratories. Detection relies on RT-PCR methods with uncertain sensitivity and limited routine use.
FINANCIAL IMPACT ON FARM'S COST OF PRODUCTION
Level: Minor: Low prevalence, typically non-lethal infection with recovery very likely
Most infections are subclinical or associated with mild diarrhea. There is no evidence of sustained or large-scale production losses.
EFFECT ON DOMESTIC OR EXPORT MARKETS
Level: Negligible: Little or no market disruption when disease occurs on one or more farms
Porcine noroviruses are not regulated and have no known market or trade impacts.
PATHOGEN'S ABILITY TO DEVELOP AND SPREAD RESISTANCE
Level: Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments
Viral pathogen with no AMR relevance.
AMR DEVELOPMENT DRIVEN BY DISEASE MANAGEMENT
Level: Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy
Disease does not drive antimicrobial use.
AVAILABILITY OF EFFECTIVE TREATMENT OPTIONS
Level: No availability: Effective treatments not currently available in the US (or have not been developed)
No specific treatments are available or required.
AVAILABILITY OF EFFECTIVE VACCINES OR BACTERINS
Level: No availability: Effective vaccines not currently available in the US (or have not been developed)
No vaccines exist, and vaccine development has not been prioritised.
FEASIBILITY OF ERADICATING THE DISEASE FROM THE US
Level: Difficult and uncertain: Extremely difficult and with uncertain success rate, few global examples of success even at farm level
Widespread, subclinical infection and environmental persistence make eradication impractical.